Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Myasthenia Gravis

  • Author: Aashit K Shah, MD, FAAN, FANA; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
 
Updated: Mar 23, 2016
 

Practice Essentials

Myasthenia gravis (MG) is a relatively rare autoimmune disorder in which antibodies form against acetylcholine nicotinic postsynaptic receptors at the neuromuscular junction of skeletal muscles (see the image below).[1, 2] MG is sometimes identified as having an ocular and generalized form, although one is not exclusive of the other and the ocular form is considered an initial, milder form of illness that progresses to the more severe generalized form in most but not all patients.

Normal neuromuscular junction showing a presynapti Normal neuromuscular junction showing a presynaptic terminal with a motor nerve ending in an enlargement (bouton terminale): Synaptic cleft and postsynaptic membrane with multiple folds and embedded with several acetylcholine receptors.

Signs and symptoms

The presentation of MG has the following characteristics:

  • The usual initial complaint is a specific muscle weakness rather than generalized weakness
  • Extraocular muscle weakness or ptosis is present initially in 50% of patients and occurs during the course of illness in 90%
  • The disease remains exclusively ocular in only 16% of patients
  • Rarely, patients have generalized weakness without ocular muscle weakness
  • Bulbar muscle weakness is also common, along with weakness of head extension and flexion
  • Limb weakness may be more severe proximally than distally
  • Isolated limb muscle weakness is the presenting symptom in fewer than 10% of patients
  • Weakness is typically least severe in the morning and worsens as the day progresses
  • Weakness is increased by exertion and alleviated by rest
  • Weakness progresses from mild to more severe over weeks or months, with exacerbations and remissions
  • Weakness tends to spread from the ocular to facial to bulbar muscles and then to truncal and limb muscles
  • About 87% of patients have generalized disease within 13 months after onset
  • Less often, symptoms may remain limited to the extraocular and eyelid muscles for years

The following factors may trigger or worsen exacerbations:

  • Bright sunlight
  • Surgery
  • Immunization
  • Emotional stress
  • Menstruation
  • Intercurrent illness (eg, viral infection)
  • Medication (eg, aminoglycosides, ciprofloxacin, chloroquine, procaine, lithium, phenytoin, beta-blockers, procainamide, statins)

The Myasthenia Gravis Foundation of America Clinical Classification divides MG into 5 main classes and several subclasses[3] :

  • Class I: Any ocular muscle weakness; may have weakness of eye closure; all other muscle strength is normal
  • Class II: Mild weakness affecting other than ocular muscles; may also have ocular muscle weakness of any severity
  • Class IIa: Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles
  • Class IIb: Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both
  • Class III: Moderate weakness affecting other than ocular muscles; may also have ocular muscle weakness of any severity
  • Class IIIa: Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles
  • Class IIIb: Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both
  • Class IV: Severe weakness affecting other than ocular muscles; may also have ocular muscle weakness of any severity
  • Class IVa: Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles
  • Class IVb: Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both; use of a feeding tube without intubation
  • Class V: Defined by the need for intubation, with or without mechanical ventilation, except when used during routine postoperative management

See Clinical Presentation for more detail.

Diagnosis

The anti–acetylcholine receptor (AChR) antibody test for diagnosing MG has the following characteristics:

  • High specificity (up to 100% [4] )
  • Positive in as many as 90% of patients who have generalized MG
  • Positive in only 50-70% of patients who have purely ocular MG

False-positive anti-AChR antibody test results have been reported in patients with the following:

  • Thymoma without MG
  • Lambert-Eaton myasthenic syndrome
  • Small cell lung cancer
  • Rheumatoid arthritis treated with penicillamine
  • 1-3% of the population older than 70 years

Assays for the following antibodies may also be useful:

  • Anti-MuSK antibody (present in about half of patients with negative results for anti-AChR antibody)
  • Anti-lipoprotein-related protein 4 (LRP4) antibody
  • Anti-agrin antibody
  • Antistriational antibody (present in almost all patients with thymoma and MG, as well as in half of MG patients with onset of MG at 50 years or older)

Other studies are as follows:

  • Plain chest radiographs may identify a thymoma as an anterior mediastinal mass
  • Chest computed tomography is important to identify or rule out thymoma or thymic enlargement in all cases of MG
  • In strictly ocular MG, magnetic resonance imaging of the brain and orbit is helpful to evaluate for mass lesions compressing the cranial nerves or a brainstem lesion that may masquerade as ocular MG
  • Electrodiagnostic studies (repetitive nerve stimulation and single-fiber electromyography)

See Workup for more detail.

Management

With recent advances in understanding the various underlying antibodies that cause myasthenia gravis and differences in how they present clinically and respond to various therapies, it is suggested that patients with myasthenia gravis should be classified into subgroups. Subgroups based on serum antibodies and clinical features may include early-onset, late-onset, and patients with thymoma, MuSK, LRP4, antibody-negative, and ocular forms of myasthenia gravis.[5]

Therapy for MG includes the following:

  • Anticholinesterase (AchE) inhibitors
  • Immunomodulating agents
  • Intravenous immune globulin (IVIg)
  • Plasmapheresis
  • Thymectomy

AchE inhibitors

  • Initial treatment for mild MG
  • Pyridostigmine is used for maintenance therapy [6, 7]
  • Neostigmine is generally used only when pyridostigmine is unavailable
  • Corticosteroid therapy provides a short-term benefit
  • Azathioprine, usually after a dose of corticosteroids, is the mainstay of therapy for difficult cases
  • Cyclosporine A and occasionally methotrexate and cyclophosphamide are used for severe cases

IVIg

  • Moderate or severe MG worsening into crisis (no value in mild disease) [8]
  • Elderly patients
  • Patients with complex comorbid diseases (eg, acute respiratory failure) [9]
  • Patients with severe weakness poorly controlled with other agents

Plasmapheresis

  • Generally reserved for myasthenic crisis and refractory cases
  • Also effective in preparation for surgery
  • Improvement is noted in a couple of days, but does not last for more than 2 months
  • Can be used long-term on a regular weekly or monthly basis can be used if other treatments cannot control the disease

Thymectomy

  • The standard of care for all patients with thymoma and for patients aged 10-55 years without thymoma but with generalized MG
  • Proposed as a first-line therapy in most patients with generalized myasthenia
  • In ocular MG, should be delayed at least 2 years to allow for spontaneous remission
  • Not recommended in patients with antibodies to muscle-specific kinase (MuSK)
  • Controversial in prepubescent patients and, to a lesser extent, patients older than 55 years

See Treatment and Medication for more detail.

Next

Background

Myasthenia gravis (MG) is a relatively rare autoimmune disorder in which antibodies form against nicotinic acetylcholine (ACh) postsynaptic receptors at the neuromuscular junction (NMJ) of the skeletal muscles. The basic pathology is a reduction in the number of ACh receptors (AChRs) at the postsynaptic muscle membrane brought about by an acquired autoimmune reaction producing anti-AChR antibodies.

The reduction in the number of AChRs results in a characteristic pattern of progressively reduced muscle strength with repeated use and recovery of muscle strength after a period of rest. The ocular and bulbar muscles are affected most commonly and most severely, but most patients also develop some degree of fluctuating generalized weakness.[10] The most important aspect of MG in emergency situations is acute worsening of weakness and diagnosis of myasthenic versus cholinergic crisis and its management.

MG is a treatable and, at times, curable neurologic disorder. Pharmacologic therapy includes anticholinesterase medication and immunosuppressive agents, such as corticosteroids, azathioprine, cyclosporine, plasmapheresis, and intravenous immune globulin (IVIg). Plasmapheresis and thymectomy are also employed to treat MG. Thymectomy is an especially important option if a thymoma is present. Patients with MG require close follow-up care in cooperation with the primary care physician.

Previous
Next

Anatomy

In MG, autoantibodies (immunoglobulin G [IgG]) develop against ACh nicotinic postsynaptic receptors at the NMJ of skeletal muscles.[1, 2] The reasons for this development are unknown, although it is clear that certain genotypes are more susceptible.[11] To understand MG, it is necessary to be familiar with the normal anatomy and functioning of the NMJ.

The nerve terminal of the motor nerve enlarges at its end to form the so-called bouton terminale, or terminal bulb. This bulb lies within a groove or indentation along the muscle fiber. The presynaptic membrane (on the nerve), postsynaptic membrane (on the muscle membrane), and the synaptic cleft (the space between the 2 membranes) together constitute the NMJ (see the image below).

Normal neuromuscular junction showing a presynapti Normal neuromuscular junction showing a presynaptic terminal with a motor nerve ending in an enlargement (bouton terminale): Synaptic cleft and postsynaptic membrane with multiple folds and embedded with several acetylcholine receptors.

ACh molecules are hydrolyzed by the enzyme acetylcholinesterase (AChE), which is abundantly present at the NMJ. The surface area of the postsynaptic membrane is increased by infolding of the membrane adjacent to the nerve terminal. This increase in surface area enables the NMJ to utilize the ACh fully. AChRs are present in small quantities over most of the muscle membrane surface but are concentrated heavily at the tips of the NMJs.

Adult AChR comprises 5 subunits (2 alpha, 1 beta, 1 gamma, and 1 delta), each of which is a membrane-spanning protein molecule. These subunits are homologous across different species, suggesting that the encoding genes evolved from a common ancestral gene. The subunits are arranged in a circle, forming a central opening that acts as an ion channel (see the image below). When an ACh molecule binds to an AChR, the AChR undergoes a 3-dimensional conformational change that opens the channel.

Acetylcholine receptor. Note 5 subunits, each with Acetylcholine receptor. Note 5 subunits, each with 4 membrane-spanning domains forming a rosette with a central opening. The central opening acts as an ion channel.

The presynaptic terminal contains vesicles filled with ACh. When an action potential travels down a motor nerve and reaches the nerve terminal, the contents of these vesicles are released into the synaptic cleft in a calcium-dependent manner. The released ACh molecules diffuse across the synapse and bind to the AChRs at the peaks of the folds on the postsynaptic membrane.

This binding causes the ion channels in the AChR to open briefly, allowing sodium ions into the interior of the muscle cell and thereby bringing about partial depolarization of the postsynaptic membrane and generation of an excitatory postsynaptic potential (EPSP). If the number of open sodium channels reaches a threshold value, a self-propagating muscle action potential is generated in the postsynaptic membrane.

Previous
Next

Pathophysiology

With every nerve impulse, the amount of ACh released by the presynaptic motor neuron normally decreases because of a temporary depletion of the presynaptic ACh stores (a phenomenon referred to as presynaptic rundown).

In MG, there is a reduction in the number of AChRs available at the muscle endplate and flattening of the postsynaptic folds. Consequently, even if a normal amount of ACh is released, fewer endplate potentials will be produced, and they may fall below the threshold value for generation of an action potential. The end result of this process is inefficient neuromuscular transmission.

Inefficient neuromuscular transmission together with the normally present presynaptic rundown phenomenon results in a progressive decrease in the amount of muscle fibers being activated by successive nerve fiber impulses. This explains the fatigability seen in MG patients.

Patients become symptomatic once the number of AChRs is reduced to approximately 30% of normal. The cholinergic receptors of smooth and cardiac muscle have a different antigenicity than skeletal muscle and usually are not affected by the disease.

The decrease in the number of postsynaptic AChRs is believed to be due to an autoimmune process whereby anti-AChR antibodies are produced and block the target receptors, cause an increase the turnover of the receptors, and damage the postsynaptic membrane in a complement-mediated manner.

Clinical observations support the idea that immunogenic mechanisms play important roles in the pathophysiology of MG. Such observations include the presence of associated autoimmune disorders (eg, autoimmune thyroiditis, systemic lupus erythematosus [SLE], and rheumatoid arthritis [RA]) in patients with MG.

Moreover, infants born to myasthenic mothers can develop a transient myasthenialike syndrome. Patients with MG will have a therapeutic response to various immunomodulating therapies, including plasmapheresis, corticosteroids, intravenous immunoglobulin (IVIg), other immunosuppressants, and thymectomy.

Anti-AChR antibody is found in approximately 80-90% of patients with MG. Experimental observations supporting an autoimmune etiology of MG include the following:

  • Induction of a myasthenialike syndrome in mice by injecting a large quantity of immunoglobulin G (IgG) from MG patients (ie, passive transfer experiments)
  • Demonstration of IgG and complement at the postsynaptic membrane in patients with MG
  • Induction of a myasthenialike syndrome in rabbits immunized against AChR by injecting them with AChR isolated from Torpedo californica (the Pacific electric ray)

The exact mechanism of loss of immunologic tolerance to AChR, a self-antigen, is not understood. MG can be considered a B cell–mediated disease, in that it derives from antibodies (a B cell product) against AChR. However, the importance of T cells in the pathogenesis of MG is becoming increasingly apparent. The thymus is the central organ in T cell–mediated immunity, and thymic abnormalities such as thymic hyperplasia or thymoma are well recognized in myasthenic patients.

Antibody response in MG is polyclonal. In an individual patient, antibodies are composed of different subclasses of IgG. In most instances, 1 antibody is directed against the main immunogenic region (MIR) on the alpha subunit. The alpha subunit is also the site of ACh binding, though the binding site for ACh is not the same as the MIR. Binding of AChR antibodies to AChR results in impairment of neuromuscular transmission in several ways, including the following:

  • Cross-linking 2 adjacent AChRs with anti-AChR antibody, thus accelerating internalization and degradation of AChR molecules
  • Causing complement-mediated destruction of junctional folds of the postsynaptic membrane
  • Blocking the binding of ACh to AChR
  • Decreasing the number of AChRs at the NMJ by damaging the junctional folds on the postsynaptic membrane, thereby reducing the surface area available for insertion of newly synthesized AChRs

Patients without anti-AChR antibodies are recognized as having seronegative MG (SNMG). Many patients with SNMG have antibodies against muscle-specific kinase (MuSK). MuSK plays a critical role in postsynaptic differentiation and clustering of AChRs. Patients with anti-MuSK antibodies are predominantly female, and respiratory and bulbar muscles are frequently involved. Another group has reported patients who exhibit prominent neck, shoulder, and respiratory weakness.[12, 13]

The role of the thymus in the pathogenesis of MG is not entirely clear, but 75% of patients with MG have some degree of thymus abnormality (eg, hyperplasia or thymoma). Histopathologic studies have shown prominent germinal centers. Epithelial myoid cells normally present in the thymus do resemble skeletal muscle cells and possess AChRs on their surface membrane. These cells may become antigenic and unleash an autoimmune attack on the muscular endplate AChRs by molecular mimicry.

The question of why MG afflicts the extraocular muscles first and predominantly remains unanswered. The answer probably has to do with the physiology and antigenicity of the muscles in question.

Previous
Next

Etiology

MG is idiopathic in most patients. Although the main cause behind its development remains speculative, the end result is a derangement of immune system regulation. MG is clearly an autoimmune disease in which the specific antibody has been characterized completely. In as many as 90% of generalized cases, IgG to AChR is present.[14] Even in patients who do not develop clinical myasthenia, anti-AChR antibodies can sometimes be demonstrated.

Patients who are negative for anti-AChR antibodies may be seropositive for antibodies against MuSK. Muscle biopsies in these patients show myopathic signs with prominent mitochondrial abnormalities, as opposed to the neurogenic features and atrophy frequently found in MG patients positive for anti-AChR. The mitochondrial impairment could explain the oculobulbar involvement in anti-MuSK–positive MG.[15]

Numerous findings have been associated with MG. For example, females and people with certain human leukocyte antigen (HLA) types have a genetic predisposition to autoimmune diseases. The histocompatibility complex profile includes HLA-B8, HLA-DRw3, and HLA-DQw2 (though these have not been shown to be associated with the strictly ocular form of MG). Both SLE and RA may be associated with MG.

Sensitization to a foreign antigen that has cross-reactivity with the nicotinic ACh receptor has been proposed as a cause of myasthenia gravis, but the triggering antigen has not yet been identified.

Various drugs may induce or exacerbate symptoms of MG, including the following:

  • Antibiotics (eg, aminoglycosides, polymyxins, ciprofloxacin, erythromycin, and ampicillin)
  • Penicillamine - This can induce true myasthenia, with elevated anti-AChR antibody titers seen in 90% of cases; however, the weakness is mild, and full recovery is achieved weeks to months after discontinuance of the drug
  • Beta-adrenergic receptor blocking agents (eg, propranolol and oxprenolol)
  • Lithium
  • Magnesium
  • Procainamide
  • Verapamil
  • Quinidine
  • Chloroquine
  • Prednisone
  • Timolol (ie, a topical beta-blocking agent used for glaucoma)
  • Anticholinergics (eg, trihexyphenidyl)
  • Neuromuscular blocking agents (eg, vecuronium and curare) - These should be used cautiously in myasthenic patients to avoid prolonged neuromuscular blockade

Nitrofurantoin has also been linked to the development of ocular MG in 1 case report; discontinuance of the drug resulted in complete recovery.

Thymic abnormalities are common: Of patients with MG, 75% have thymic disease, 85% have thymic hyperplasia, and 10-15% have thymoma. Extrathymic tumors may include small cell lung cancer and Hodgkin disease.[16, 17] Hyperthyroidism is present in 3-8% of patients with MG and has a particular association with ocular MG.

Previous
Next

Epidemiology

United States statistics

MG is uncommon. The estimated annual US incidence is 2 per 1,000,000. The prevalence of MG in the United States ranges from 0.5 to 14.2 cases per 100,000 people. This figure has risen over the past 2 decades, primarily because of the increased lifespan of patients with MG but also because of earlier diagnosis.[6] About 15-20% of patients will experience a myasthenic crisis. Three fourths of these patients experience their first crisis within 2 years of diagnosis.[11]

International statistics

In the United Kingdom, the prevalence of MG is 15 cases per 100,000 population. In Croatia, it is 10 cases per 100,000. In Sardinia, Italy, the prevalence increased from 0.75 per 100,000 in 1958 to 4.5 cases per 100,000 in 1986.

Age-related demographics

MG can occur at any age. Female incidence peaks in the third decade of life, whereas male incidence peaks in the sixth or seventh decade. The mean age of onset is 28 years in females and 42 years in males.

Transient neonatal MG occurs in infants of myasthenic mothers who acquire anti-AChR antibodies via placental transfer of IgG. Some of these infants may suffer from transient neonatal myasthenia due to effects of these antibodies.

Most infants born to myasthenic mothers possess anti-AChR antibodies at birth, yet only 10-20% develop neonatal MG. This may be due to protective effects of alpha-fetoprotein, which inhibits binding of anti-AChR antibody to AChR. High maternal serum levels of AChR antibody may increase the chance of neonatal MG; thus, lowering the maternal serum titer during the antenatal period by means of plasmapheresis may be useful.

Sex-related demographics

Classically, the overall female-to-male ratio has been considered to be 3:2, with a female predominance in younger adults (ie, patients aged 20-30 years) and a slight male predominance in older adults (ie, patients older than 50 years).[6, 10] Studies show, however, that with increased life expectancy, males are coming to be affected at the same rate as females. Ocular MG shows a male preponderance. The male-to-female ratio in children with MG and another autoimmune condition is 1:5.

Race-related demographics

The onset of MG at a young age is slightly more common in Asians than in other races.[6]

Previous
Next

Prognosis

Given current treatment, which combines cholinesterase inhibitors, immunosuppressive drugs, plasmapheresis, immunotherapy, and supportive care in an intensive care unit (ICU) setting (when appropriate), most patients with MG have a near-normal life span. Mortality is now 3-4%, with principal risk factors being age older than 40 years, short history of progressive disease, and thymoma; previously, it was as high as 30-40%. In most cases, the term gravis is now a misnomer.

Morbidity results from intermittent impairment of muscle strength, which may cause aspiration, increased incidence of pneumonia, falls, and even respiratory failure if not treated.[14] In addition, the medications used to control the disease may produce adverse effects.

Today, the only feared condition arises when the weakness involves the respiratory muscles. Weakness might become so severe as to require ventilatory assistance. Those patients are said to be in myasthenic crisis.

The disease frequently presents (40%) with only ocular symptoms. However, the extraocular almost always are involved within the first year. Of patients who show only ocular involvement at the onset of MG, only 16% still have exclusively ocular disease at the end of 2 years.

In patients with generalized weakness, the nadir of maximal weakness usually is reached within the first 3 years of the disease. As a result, half of the disease-related mortality also occurs during this period. Those who survive the first 3 years of disease usually achieve a steady state or improve. Worsening of disease is uncommon after 3 years.

Thymectomy results in complete remission of the disease in a number of patients. However, the prognosis is highly variable, ranging from remission to death.

A retrospective study of 38 patients with MG indicates that the disease, particularly late-onset MG, is associated with a high risk for cancers outside of the thymus, whether or not the patient also has, as is common in MG, a thymoma.[16] Extrathymic neoplasms occurred in 12 of the study patients; all of these tumors were solid and heterogeneous to their organ of origin. Some of the tumors were diagnosed before and some after the patients were diagnosed with MG.

Altogether the tumors represented 9 different types of neoplasm, as follows:

  • 2 each of squamous cell carcinoma of the mouth, invasive bladder cancer, and prostate adenocarcinoma
  • 1 each of basal cell skin cancer; lung, gastric, breast, and colon adenocarcinoma; and renal cell cancer

The only statistically significant variable among the patients was age, with the extrathymic tumors being found only in patients over 50 years. None of the patients with these neoplasms had thyroid disease or an autoimmune disease other than MG.

Previous
Next

Patient Education

Educate patients to recognize and immediately report impending respiratory crisis. Intercurrent infection may worsen symptoms of MG temporarily. Mild exacerbation of weakness is possible in hot weather.

The risk of congenital deformity (arthrogryposis multiplex) is increased in offspring of women with severe MG. Neonates born to women with MG must be monitored for respiratory failure for 1-2 weeks after birth. Certain immunosuppressant drugs have teratogenic potential. Discuss these aspects with women in reproductive years before beginning therapy with these drugs.

Certain medications (eg, aminoglycosides, ciprofloxacin, chloroquine, procaine, lithium, phenytoin, beta-blockers, procainamide, and quinidine) may exacerbate symptoms of MG; many others have been associated only rarely with exacerbation of MG. Patients should always consult a neurologist before starting any of these medications.

Medications that induce the hepatic microsomal cytochrome P-450 system (eg, corticosteroids) may render oral contraceptives less effective.

Statins may cause worsening of myasthenia without regard to type of MG or brand of statin. Worsening of weakness can occur independent of myalgic syndrome and usually involves oculobulbar symptoms within 1-16 weeks of the initiation of statin treatment.[18]

Previous
 
 
Contributor Information and Disclosures
Author

Aashit K Shah, MD, FAAN, FANA Professor and Associate Chair of Neurology, Director, Comprehensive Epilepsy Program, Program Director, Clinical Neurophysiology Fellowship, Detroit Medical Center, Wayne State University School of Medicine

Aashit K Shah, MD, FAAN, FANA is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Received consulting fee from UCB pharma for speaking and teaching; Received grant/research funds from UCB Pharma for other; Received consulting fee from Sunovion for speaking and teaching; Received consulting fee from Lundbeck for speaking and teaching.

Coauthor(s)

William D Goldenberg, MD Assistant Professor, Department of Emergency Medicine, Uniformed Services University of Health Sciences; Staff Emergency Physician, Naval Hospital San Diego

William D Goldenberg, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Society for Academic Emergency Medicine, Emergency Medicine Residents' Association

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Acknowledgements

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Baxter Grant/research funds Other; Amgen Grant/research funds None

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Strauss AJL, Seigal BC, Hsu KC. Immunofluorescence demonstration of a muscle binding complement fixing serum globulin fraction in Myasthenia Gravis. Proc Soc Exp Biol. 1960. 105:184.

  2. Patric J, Lindstrom JM. Autoimmune response to acetylcholine receptor. Science. 1973. 180:871.

  3. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000 Jul 12. 55(1):16-23. [Medline].

  4. Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol. 2000 Jul. 111(7):1203-7. [Medline].

  5. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct. 14 (10):1023-36. [Medline].

  6. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004 Apr. 29(4):484-505. [Medline].

  7. Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol. 2004 Mar. 24(1):41-8. [Medline].

  8. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007 Mar 13. 68(11):837-41. [Medline].

  9. Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010 Dec. 68(6):797-805. [Medline].

  10. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008 Feb. 37(2):141-9. [Medline].

  11. Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008 Jan. 101(1):63-9. [Medline].

  12. Evoli A, Tonali PA, Padua L. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003 Oct. 126(Pt 10):2304-11. [Medline].

  13. Sanders DB, Howard JF, Massey JM. Seronegative myasthenia gravis. Ann Neurol. 1987. 22:126.

  14. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008 Jan 23. CD002277. [Medline].

  15. Martignago S, Fanin M, Albertini E, Pegoraro E, Angelini C. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol. 2009 Feb. 35(1):103-10. [Medline].

  16. Keller DM. Late-Onset Myasthenia Gravis Linked to Higher Cancer Risk. Medscape Medical News. Jul 2 2013. [Full Text].

  17. Liu CJ, Chang YS, Teng CJ, et al. Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol. 2012 May. 19(5):746-51. [Medline].

  18. Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008 Sep. 38(3):1101-7. [Medline]. [Full Text].

  19. Harding A. Pediatric Myasthenia Diagnosis Can Be Challenging, Study Shows. Medscape Medical News. Available at http://www.medscape.com/viewarticle/811117. Accessed: September 23, 2013.

  20. Vanderpluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical Characteristics of Pediatric Myasthenia: A Surveillance Study. Pediatrics. 2013 Sep 9. [Medline].

  21. Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. 2nd ed. 1994. 1769-1797.

  22. J P Sieb. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. March 2014. 175(3):408–418. [Full Text].

  23. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011 Jul. 44 (1):36-40. [Medline].

  24. Qureshi AI, Choundry MA, Mohammad Y, et al. Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monit. 2004 Dec. 10(12):CR684-9. [Medline].

  25. Tindall RS. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol. 1981 Nov. 10(5):437-47. [Medline].

  26. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001 Mar. 7(3):365-8. [Medline].

  27. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol. 2005 Sep. 116(9):2065-8. [Medline].

  28. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010 Mar. 41(3):370-4. [Medline].

  29. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003 Jun 24. 60(12):1978-80. [Medline].

  30. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012 Apr. 69 (4):445-51. [Medline].

  31. Romi F, Skeie GO, Gilhus NE. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. 2005 Mar. 62(3):442-6. [Medline].

  32. Phillips LH 2nd, Melnick PA. Diagnosis of myasthenia gravis in the 1990s. Semin Neurol. 1990 Mar. 10(1):62-9. [Medline].

  33. Toth L, Toth A, Dioszeghy P, Repassy G. Electronystagmographic analysis of optokinetic nystagmus for the evaluation of ocular symptoms in myasthenia gravis. Acta Otolaryngol. 1999. 119(6):629-32. [Medline].

  34. Yang Q, Wei M, Sun F, Tian J, Chen X, Lu C. Open-loop and closed-loop optokinetic nystagmus (OKN) in myasthenia gravis and nonmyasthenic subjects. Exp Neurol. 2000 Nov. 166(1):166-72. [Medline].

  35. Movaghar M, Slavin ML. Effect of local heat versus ice on blepharoptosis resulting from ocular myasthenia. Ophthalmology. 2000 Dec. 107(12):2209-14. [Medline].

  36. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006 Jul. 16(7):459-67. [Medline].

  37. Pascuzzi RM. Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders. Semin Neurol. 2001 Dec. 21(4):425-40. [Medline].

  38. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003 Dec 23. 61(12):1652-61. [Medline].

  39. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005 Apr 18. CD002828. [Medline].

  40. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol. 2003 Jan. 53(1):29-34. [Medline].

  41. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25. 61(10):1438-40. [Medline].

  42. Lisak RP. Myasthenia Gravis. Curr Treat Options Neurol. 1999 Jul. 1(3):239-250. [Medline].

  43. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics. 2008 Oct. 5(4):535-41. [Medline].

  44. [Guideline] Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007 Jun 12. 68(24):2144-9. [Medline].

  45. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007 Oct 17. CD005224. [Medline].

  46. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004 May 19. 291(19):2367-75. [Medline].

  47. Zinman L, Bril V. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies. Ann N Y Acad Sci. 2008. 1132:264-70. [Medline].

  48. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012 Jan 17. 78 (3):189-93. [Medline].

  49. Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005 Mar. 57(3):444-8. [Medline].

  50. Takanami I, Abiko T, Koizumi S. Therapeutic outcomes in thymectomied patients with myasthenia gravis. Ann Thorac Cardiovasc Surg. 2009 Dec. 15(6):373-7. [Medline].

  51. Nieto IP, Robledo JP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg. 1999 Jun. 67(6):1568-71. [Medline].

  52. Goldstein SD, Yang SC. Assessment of robotic thymectomy using the Myasthenia Gravis Foundation of America Guidelines. Ann Thorac Surg. 2010 Apr. 89(4):1080-5; discussion 1085-6. [Medline].

  53. Marulli G, Schiavon M, Perissinotto E, et al. Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis. J Thorac Cardiovasc Surg. 2013 Mar. 145(3):730-5; discussion 735-6. [Medline].

  54. Brooks M. PLEX and IVIG both effective maintenance options in juvenile MG. Reuters Health Information. March 6, 2014. [Full Text].

  55. Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014 Mar 3. [Medline].

 
Previous
Next
 
Normal neuromuscular junction showing a presynaptic terminal with a motor nerve ending in an enlargement (bouton terminale): Synaptic cleft and postsynaptic membrane with multiple folds and embedded with several acetylcholine receptors.
Acetylcholine receptor. Note 5 subunits, each with 4 membrane-spanning domains forming a rosette with a central opening. The central opening acts as an ion channel.
CT scan of chest showing an anterior mediastinal mass (thymoma) in a patient with myasthenia gravis.
Increasing left ptosis developing upon sustained upward gaze in patient with myasthenia gravis (A through F). Note limited elevation of left eye, denoting superior rectus palsy (A). A initially, C after around 20 seconds, F after 1 minute.
Cogan sign. Patient changes gaze from downward position (A) to primary position (B). Both lids are seen to overshoot in twitch (B) before gaining their initial ptotic position (D). In this case, Cogan sign is seen more obviously on right, whereas left lid is more ptotic.
CT scan of chest and mediastinum showing thymoma in patient with myasthenia gravis.
Repetitive nerve stimulation at frequency of 2 Hz showing increasing decrement in amplitude of compound muscle action potential up to fourth response (42% amplitude loss), after which it stabilizes.
Single-fiber electromyography showing so-called jitter phenomenon (second action potential wave group).
Table. Prevalence and Titers of Antibody to Acetylcholine Receptor in Patients with Myasthenia Gravis
Osserman MG Class* Mean Anti-AChR Titer (× 10–9 M) Positive Results, %
R 0.79 24
I 2.17 55
IIA 49.8 80
IIB 57.9 100
III 78.5 100
IV 205.3 89
AChR = acetylcholine receptor; MG = myasthenia gravis.



*Osserman classification: R = remission, I = ocular only, IIA = mild generalized, IIB = moderate generalized, III = acute severe, IV = chronic severe.



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.